What is it about?
There are over 100 genes that are strongly associated with autism, yet advancing from risk genes to drug candidates is a central challenge. In this study, we leverage key advantages of larval zebrafish to screen hundreds of U.S. FDA-approved drugs and generate a database of their effects on basic sleep and sensory processing behaviors. Using this database, we identify drug candidates capable of reversing dysregulated behaviors in zebrafish lacking the function of two autism risk genes.
Featured Image
Photo by Warren Umoh on Unsplash
Why is it important?
Our study identifies estrogens, microtubules, mitochondria, and lipid metabolism as central pathways relevant to specific autism risk genes. We found that levocarnitine, a drug that transports long-chain fatty acids into mitochondria, is a top rescue drug for two autism risk genes. These findings lay the groundwork for investigating whether levocarnitine or other drugs regulating these pathways might represent a target for individuals carrying mutations in these genes. Our study highlights the importance of subgrouping autism risk genes to identify drug candidates using a precision medicine-based approach.
Perspectives
As a practicing physician, I am aware of the need for improved, targeted treatments relevant to specific autism risk genes. I am excited by the promise of large-scale zebrafish screens to identify drug candidates that might represent targetable pathways for individuals carrying mutations in a subset of genes, which can be investigated further in future studies.
Ellen Hoffman
Yale University
Read the Original
This page is a summary of: Pharmaco-behavioral profiling identifies suppressors of autism gene–associated phenotypes in zebrafish, Proceedings of the National Academy of Sciences, March 2026, Proceedings of the National Academy of Sciences,
DOI: 10.1073/pnas.2518846123.
You can read the full text:
Resources
Contributors
The following have contributed to this page
